UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029044
Receipt number R000033178
Scientific Title The study on effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis
Date of disclosure of the study information 2019/04/01
Last modified on 2020/09/09 13:41:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study on effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

Acronym

Effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

Scientific Title

The study on effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

Scientific Title:Acronym

Effectiveness of sublingual immunotherapy with mite extract in patients with atopic dermatitis

Region

Japan


Condition

Condition

Atopic dermatitis

Classification by specialty

Clinical immunology Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the effectiveness of sublingual immunotherapy on symptom improvement in patients with atopic dermatitis which have perennial allergic rhinitis

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Eczema Area and Severity Index score (1,3,6,12,18,24 months after initiation of sublingual immunotherapy)

Key secondary outcomes

skin test, specific IgE, serum TARC, itchy severity index (VAS), Nasal symptom score


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

sublingual tablet for house dust mite 3,300 JAU was selected as the initial dose for a week, followed by upward titration of the dose to 10,000 JAU, and continue for 2 years

Interventions/Control_2

Non-intervention

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Symptom of rhinitis on medical history
(2) Upper than 5 in EASI score
(3) Patients with positive skin test and specific IgE antibody for house dust mite
(4) Patients who agree with this examination
(5) Older than 20 years

Key exclusion criteria

(1) Pregnant and breast-feeding patients
(2) Patients with severe asthma
(3) Patients who take oral corticosteroid and cyclosporine
(4) Inappropriate patients in this examination

Target sample size

32


Research contact person

Name of lead principal investigator

1st name Chikako
Middle name
Last name Nishigori

Organization

Kobe University Graduate School of Medicine

Division name

Division of Dermatology, Department of Internal Related

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

TEL

078-382-6134

Email

chikako@ed.kobe-u.ac.jp


Public contact

Name of contact person

1st name Mayuko
Middle name
Last name Mizuno

Organization

Kobe University Graduate School of Medicine

Division name

Division of Dermatology, Department of Internal Related

Zip code

650-0017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

TEL

078-382-6134

Homepage URL


Email

196m858m@stu.kobe-u.ac.jp


Sponsor or person

Institute

Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee at Kobe University Hospital

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Tel

078-382-6669

Email

kainyu@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

12

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 09 Month 07 Day

Date of IRB

2018 Year 03 Month 12 Day

Anticipated trial start date

2018 Year 03 Month 12 Day

Last follow-up date

2020 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete

2020 Year 10 Month 31 Day

Date analysis concluded

2021 Year 06 Month 01 Day


Other

Other related information



Management information

Registered date

2017 Year 09 Month 07 Day

Last modified on

2020 Year 09 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033178


Research Plan
Registered date File name
2019/05/10 研究計画書20180313.docx

Research case data specifications
Registered date File name

Research case data
Registered date File name